Literature DB >> 17333054

[Endocrine disorders and the heart].

Onno E Janssen1, K Mann, R Erbel.   

Abstract

Hormonal regulation is not possible without the cardiovascular system, and thus the heart plays a special role not only in the action and synthesis, but also in the distribution of hormones. Severe endocrine disorders with cardiac involvement are often threatening for the patient. The impact of aberrant thyroid function, the sympathetic-adrenal symptoms of which predominantly affect the heart, is well known. Diabetes mellitus and the associated metabolic syndrome are major causes of cardiovascular disease and determine its morbidity and lethality rates. Acromegaly causes a complex cardiomyopathy that may result in cardiac failure refractive to conventional treatment. The excessive production of adrenal hormones in Cushing's syndrome, hyperaldosteronism and pheochromocytoma primarily harms the heart by causing severe hypertension. The same holds true for long-standing hyperparathyroidism. Recent prospective studies did not confirm the protective effect of hormone replacement therapy on cardiovascular disease.

Entities:  

Mesh:

Year:  2007        PMID: 17333054     DOI: 10.1007/s00108-007-1807-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  26 in total

1.  Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease.

Authors:  Gerald Reaven
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

2.  Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy.

Authors:  Burkhard L Herrmann; C Bruch; B Saller; T Bartel; S Ferdin; R Erbel; K Mann
Journal:  Clin Endocrinol (Oxf)       Date:  2002-05       Impact factor: 3.478

Review 3.  Acromegaly and the cardiovascular system.

Authors:  Gaetano Lombardi; Mariano Galdiero; Renata S Auriemma; Rosario Pivonello; Annamaria Colao
Journal:  Neuroendocrinology       Date:  2006       Impact factor: 4.914

Review 4.  Growth hormone and the metabolic syndrome.

Authors:  G Johannsson; B A Bengtsson
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

5.  [Intima-media thickness in healthy probands without risk factors for arteriosclerosis].

Authors:  T Temelkova-Kurktschiev; S Fischer; C Koehler; G Mennicken; E Henkel; M Hanefeld
Journal:  Dtsch Med Wochenschr       Date:  2001-02-23       Impact factor: 0.628

6.  Insulin sensitivity and coronary vasoreactivity: insulin sensitivity relates to adenosine-stimulated coronary flow response in human subjects.

Authors:  N Dagres; B Saller; M Haude; J Hüsing; C von Birgelen; A Schmermund; S Sack; D Baumgart; K Mann; R Erbel
Journal:  Clin Endocrinol (Oxf)       Date:  2004-12       Impact factor: 3.478

Review 7.  Insulin resistance syndrome and polycystic ovary syndrome: implications for diagnosis and treatment.

Authors:  S Tan; S Hahn; O E Janssen
Journal:  Panminerva Med       Date:  2005-12       Impact factor: 5.197

8.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.